Assessing the current treatment of atopic dermatitis: Unmet needs - 19/04/17
Key words : Atopic dermatitis, eczema, immune, therapy
Le texte complet de cet article est disponible en PDF.
Disclosure of potential conflict of interest: D. Y. M. Leung receives grant support form MedImmune; serves as a consultant for Novartis, Regeneron, and Sanofi-Aventis; and receives payments for reviewing from Omnia-Prova Education Collaborative. E. Guttman-Yassky serves on the board for Sanofi-Aventis, Regeneron, Stiefel/GlaxoSmithKline, MedImmune, Celgene, Anacor, Leo Pharma, AnaptysBio, Celsus, Dermira, Galderma, Novartis, Pfizer, Vitae, Glenmark, AbbVie, and Asana Biosciences; serves as a consultant for Regeneron, Sanofi-Aventis, MedImmune, Celgene, Stiefel/GlaxoSmithKline, Celsus, BMS, Amgen, Drais, AbbVie, Anacor, AnaptysBio, Dermira, Galderma, Leo Pharma, Novartis, Pfizer, Vitae Mitsubishi Tanabe, Eli Lilly, Glenmark, and Asana Biosciences; and receives grant support from Regeneron, Celgene, BMS, Janssen, Dermira, Leo Pharma, Merck, Novartis, and UCB. |
Vol 139 - N° 4S
P. S47-S48 - avril 2017 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?